Coordinates: 53°21′22″N 83°45′43″E / 53.356°N 83.762°E / 53.356; 83.762Altai State Medical University (Russian: Алтайский государственный медицинский университет) is a public university in Barnaul, Russia. The university was known as Altai State Medical Institute until 1994. Altai State Medical University is located in the West Siberian part of the country. It is functioned by more than 60 departments and has seven faculties..
Netakimab is a humanized anti-interleukin-17A monoclonal antibody, it has marketing approval for treatment of adult patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This paper provides the results of the first 12-week period of phase III BCD-085-16/PLANETA-KIDS clinical study.Objective. The aim of the BCD-085-16/PLANETA-KIDS is to evaluate netakimab efficacy and safety in pediatric patients 6+ years old with moderate-to-severe plaque psoriasis.Methods. BCD-085-16/PLANETA-KIDS (NCT06640517) is a randomized, double-blind, placebo-controlled phase III clinical study with open-label active-comparator arm (adalimumab). A total of 155 male and female patients aged from 6 to 18 years with confirmed moderate-to-severe plaque psoriasis were randomized to receive netakimab (n = 83), placebo (n = 35), or adalimumab (n = 37). Netakimab dosage was weight adjusted: for patients weighing 50 kg or more netakimab dose was 120 mg (two injections of 60 mg/ml each), for patients weighing less than 50 kg netakimab dose was 60 mg (one injection of 60 mg/ml). Patients in the Netakimab group received netakimab subcutaneously once per week for the first three weeks (induction) and once every 4 weeks thereafter (maintenance). Patients in the Placebo group received placebo in blinded manner like netakimab. Adalimumab was administered in open-label way in doses recommended by the product’s SmPC. In this study co-primary efficacy endpoints were the proportion of patients achieving PASI75 and sPGA0/1 at week 12.Results. Netakimab has shown superiority over placebo for both co-primary endpoints. The proportion of patients achieving PASI75 at week 12 was 89.2% in the Netakimab group and 14.3% in the Placebo group, odds ratio (OR) 59.0, 95% CI [16.5; 211.5] (p < 0.0001). The proportion of patients achieving sPGA0/1 at week 12 was 83.1% in the Netakimab group and 8.6% in the Placebo group, OR 54.9, 95% CI [14.6; 206.5] (p < 0.0001). The subgroup analysis has shown consistent netakimab superiority over placebo for both co-primary endpoints, regardless of age, body weight and psoriasis severity. Throughout the 12-week period netakimab has shown favorable safety profile comparable to that in the Placebo group.Conclusion. The results of the 12-week period in the BCD-085-16/PLANETA-KIDS study have shown high efficacy of netakimab compared with placebo with favorable safety profile in children aged 6 years and older and adolescents with moderate-to-severe plaque psoriasis.
Введение.Монреальское консенсусное совещание определило гастроэзофагеальную рефлюксную болезнь как состояние, развивающееся, когда рефлюкс содержимого желудка вызывает беспокоящие симптомы и/или осложнения.Общемировая распространенностьгастроэзофагеальной рефлюксной болезнисоставляет 13,3% и продолжает расти.Данных о распространенности гастроэзофагеальной рефлюксной болезни в педиатрической популяции значительно меньше.Цель исследования—установить распространенность симптомов гастроэзофагеальной рефлюксной болезни у детей школьного возраста с помощью опросника Gerd-Q.Материалы и методы.Проведено исследование распространенности симптомовгастроэзофагеальной рефлюксной болезнисреди школьников города Барнаула. В исследование включен 291 школьник, из них 131 мальчик (45,0%) и 160 девочек (55,0%), учащиеся 7–11 классов общеобразовательных учреждений.Для количественной оценки распространенности симптомов гастроэзофагеальной рефлюксной болезни в детской популяции применяли валидированный опросник Gerd-Q.Статистическая значимость различий качественных признаков оценивалась с использованием критерия согласия χ2Пирсона. Различия при p <0,05 расценивали как значимые.Результаты.По данным исследования симптомовгастроэзофагеальной рефлюксной болезни, проведенного с применением анкеты Gerd-Q, распространенность гастроэзофагеальной рефлюксной болезни у детей школьного возраста составила 8,2%. Жалобы на изжогу и регургитацию с частотой не менее 1 раза в неделю предъявляли 19,6 и 35,7% школьников. Ночные симптомыгастроэзофагеальной рефлюксной болезниотмечались у 2,7% школьников. К периодическому самостоятельному приему антацидов для купирования симптомов прибегали 4,1% обследованных.Заключение.Использование анкеты Gerd-Q позволяет увеличить частоту выявления симптомов гастроэзофагеальной рефлюксной болезни, причем наиболее частым среди симптомов определяется изжога, которая беспокоит преимущественно мальчиков. Introduction.The Montreal Consensus Meeting defined gastroesophageal reflux disease as a condition that develops when reflux of gastric contents causes bothersome symptoms and/or complications. The global prevalence of gastroesophageal reflux disease is 13.3% and continues to increase. Data on the prevalence of gastroesophageal reflux disease in the pediatric population are significantly scarcer. Study.Aim—to study the prevalence of gastroesophageal reflux disease symptoms in school-aged children using the Gerd-Q questionnaire.Materials and methods.A study was conducted to assess the prevalence of gastroesophageal reflux disease symptoms among schoolchildren in Barnaul. The study included 291 schoolchildren, including 131 boys (45.0%) and 160 girls (55.0%), studying in grades 7–11 of comprehensive schools. The validated Gerd-Q questionnaire was used to quantitatively assess the prevalence of gastroesophageal reflux disease symptoms in the pediatric population. The statistical significance of differences in qualitative characteristics was assessed using the Pearson χ2goodness-of-fit test. Differences at p <0.05 were considered significant.Results.According to a study of gastroesophageal reflux disease symptoms conducted using the Gerd-Q questionnaire, the prevalence of gastroesophageal reflux disease in school-aged children was 8.2%. Heartburn and regurgitation, with a frequency of at least once a week, were reported by 19.6% and 35.7% of schoolchildren, respectively. Nocturnal gastroesophageal reflux disease symptoms were observed in 2.7% of schoolchildren. Periodic self-administration of antacids to relieve symptoms was used by 4.1% of those surveyed.Conclusion.The use of the Gerd-Q questionnaire allows to improve the frequency of detection of gastroesophageal reflux disease symptoms, and the most frequent, among school-age children, is determined by heartburn, which bothers boys predominantly.
The application of probiotic formulations is presently regarded as a promising strategy for both the treatment and prevention of acute intestinal infections (AII) in pediatric populations. Innovative methods aimed at restoring intestinal microflora are being integrated into clinical practice through the development of probiotic preparations featuring enhanced, combined compositions that aim to achieve more effective therapeutic outcomes, particularly by promoting the patient's endogenous microflora. Objective. To assess the clinical effectiveness of the probiotic formulation "Blagobifid Plus" in the combined treatment of acute intestinal infections in children. Materials and Methods. This investigation involved 60 children (the primary group) exhibiting clinical and laboratory signs of acute intestinal infection (AII), who were administered the probiotic composition (PC) "Blagobifid Plus" as part of a combination therapy regimen. To ensure the reliability of the laboratory findings, a control group was established, comprising 40 children with clinical and laboratory signs of AII who did not receive the PC. The research methodologies, procedures, and instruments employed included statistical analysis, clinical assessments, biochemical evaluations, bacteriological examinations, and immunological tests; informed consent acquisition, collection of medical history, utilization of questionnaires, review of medical records, bacteriological apparatus, and ELISA testing systems. Results. The administration of the probiotic formulation "Blagobifid Plus" at the suggested dosage, in accordance with the study protocol, as part of the comprehensive "basic" treatment for acute intestinal infections in pediatric patients, results in a decrease in stool frequency, a reduction in the duration of diarrhea, and alleviation of flatulence during the illness and within the hospital environment during the administration of the probiotic, in comparison to the control group. Conclusion. The probiotic formulation "Blagobifid Plus" has been shown to be safe and well-tolerated, with no reports of allergic reactions, individual intolerances, or adverse effects among the study participants. The optimal dosage of one capsule per day, initiated upon admission and maintained throughout the hospital stay, has been established, as the probiotic formulation "Blagobifid Plus" has proven its efficacy.
This article examines issues related to the possibility of the presence of elements of Celtic culture and their carriers of in Scandinavia during the Roman Iron Age. It has been reviewed the ethnic affiliation of many northern tribes mentioned by ancient authors is highly controversial and requires that the processes of cultivation of Scandinavian tribes be taken into account in the course of trade contacts, migrations caused by military conflicts, as well as naturally induced negative changes in habitat and its depletion during economic development. One of the reasons for the Celtic trade expansions to northeastern Europe may have been the search for sources of amber, which was highly valued in international trade, served as an intertribal exchange commodity, and also held sacred and cult significance. Archaeological and historical-anthropological research data indicate a possible Celtic presence on the Scandinavian Peninsula in Rogaland. Celtic tribes assimilated by the Germanic tribes could have represented the population of the aforementioned region.
Objective : To evaluate the impact of the severity of community-acquired pneumonia (CAP) on the clinical and functional characteristics, course, and outcomes of acute coronary syndrome that developed in the context of CAP. Materials and methods . A retrospective observational study with a case-control design element was conducted on 90 patients with acute coronary syndrome (ACS) and a history of CAP. Results . Regression analysis models revealed that hypoxemia (SpO 2 <90%), fibrinogen, troponin T, hemoglobin, and blood platelet levels, in combination with pneumonia severity and serum C-reactive protein (CRP), significantly impact tricuspid regurgitant jet velocity (TRJV), explaining 83.5% of its variability. The risk of paroxysmal atrial fibrillation increased with higher TRJV, greater pneumonia severity, and diuretic use. Conclusion . In patients with ACS combined with CAP, the role of hypoxemia and biological markers of inflammation in the development of right ventricular heart failure and paroxysmal atrial fibrillation has been established.
